Who are Zyclara®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): imiquimod cream, 3.75%, Imiquimod cream + surgery, Double-Stranded RNA sodium salt, Imiquimod Vehicle.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zyclara.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Zyclara® — Competitive Intelligence Brief

Zyclara® (Zyclara®) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Toll-like receptor agonist. Area: Dermatology/Oncology.

marketed Toll-like receptor agonist TLR7, TLR8 Dermatology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Zyclara® (Zyclara®) — Actavis Inc.. Zyclara is an imiquimod cream that activates toll-like receptors (TLR7 and TLR8) on immune cells to stimulate local and systemic immune responses against skin lesions.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Zyclara® TARGET	Zyclara®	Actavis Inc.	marketed	Toll-like receptor agonist	TLR7, TLR8
imiquimod cream, 3.75%	imiquimod cream, 3.75%	Actavis Mid-Atlantic LLC	phase 3	Immunomodulator	TLR7, TLR8
Imiquimod cream + surgery	Imiquimod cream + surgery	Nantes University Hospital	phase 3	Toll-like receptor agonist (topical immune response modifier)	TLR7, TLR8
Double-Stranded RNA sodium salt	Double-Stranded RNA sodium salt	Promomed, LLC	phase 3	Toll-like receptor agonist / Immunostimulant	TLR3 (Toll-like receptor 3)
Imiquimod Vehicle	Imiquimod Vehicle	Apotex Inc.	phase 3	Toll-like receptor agonist	TLR7/TLR8

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Toll-like receptor agonist class)

Actavis Inc. · 1 drug in this class
Apotex Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zyclara® — Competitive Intelligence Brief. https://druglandscape.com/ci/zyclara. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab